Alzheimer’s Trials Investigated; Chronic Pain Predicted; Dementia Drugs and AMD

A New York Times investigation reported that in early studies of lecanemab (Leqembi) and donanemab (Kisunla), participants were not given the opportunity to know whether they carried APOE4, a genetic variant with higher risks of brain edema and bleeding after anti-amyloid treatment.

Most older adults with no prior diagnosis of cognitive impairment who received primary care at a federally qualified health center actually had mild cognitive impairment or dementia. (JAMA Network Open)

The overall rate of emergency room visits for older adults with Alzheimer’s disease was 36.1 visits per 1,000 adults in 2020-2022; for Black Alzheimer’s patients, it was 71.3 visits per 1,000. (NCHS Data Brief)

Poor cardiovascular health in midlife was associated with a twofold higher risk of developing a composite outcome of diseases tied to poor brain health. (Neurology)

Hippocampal functional connectivity after whiplash injury predicted whether acute pain would transition to chronic pain. (Nature Mental Health)

Two commonly prescribed dementia drugs — memantine and donepezil — were not associated with a reduced risk of developing age-related macular degeneration (AMD), contrary to earlier findings. (JAMA Network Open)

Researchers identified four new dementia risk loci in a large neuropathology genome-wide association study. (Nature Genetics)

Choroid plexus volume was greater in participants with pediatric-onset multiple sclerosis than in healthy controls. (Neurology: Neuroimmunology and Inflammation)

Neurologists in Australia called for the country’s chemical regulator to ban the weedkiller paraquat due to its links with Parkinson’s disease. (ABC News)

Athletes who recalled that they had shaken their head spontaneously after at least one collision associated it with a self-reported concussion. (Diagnostics)

Please enable JavaScript to view the comments powered by Disqus.